Bath, United Kingdom – ReadyGo Diagnostics Ltd. (ReadyGo™) has announced a co-development agreement with SureScreen Diagnostics Ltd. to research, develop, and commercialize a groundbreaking product for the drink spike testing market. The partnership combines ReadyGo’s advanced Sampler technology and proprietary dried reagent technology with SureScreen’s proven assays for drug detection to create an easy-to-use consumer testing solution.
The collaboration aims to address a growing public safety concern by providing a compact, portable device that can be easily deployed in various environments, such as bars, clubs, and other licensed premises.
The new testing assay will offer comprehensive drug testing in decentralized settings, providing extensive coverage for detecting various drugs commonly used to spike drinks, including GHB, rohypnol, and ketamine. With a rapid turnaround time of just a few minutes, the test will provide quick results to help individuals make immediate decisions and prevent harm.
Designed for ease of use by non-specialized consumers, the test features simplified sample collection and processing. Its intuitive design and user-friendly operation make it suitable for use anywhere and by anyone.
“This collaboration is a significant step forward in our mission to provide innovative and accessible testing solutions to as many people as possible,” said Ben Cobb, CEO of ReadyGo Diagnostics Ltd. “By combining our innovative technology with SureScreen’s expertise in drug detection, we are creating a product that meets a growing and critical need for reliable drink spike testing for consumers who may be in vulnerable situations.”
George Newham, Research and Development Manager of SureScreen Diagnostics Ltd., added, “We are excited to partner with ReadyGo Diagnostics on this important initiative. Our joint effort will deliver a powerful tool that enhances public safety and aligns with the evolving landscape of testing in licensed premises.”
This co-development initiative reflects both companies’ commitment to innovation and public health, ensuring that timely interventions are accessible to all. The partnership aims to bring to market a highly effective and user-friendly testing solution that can make a real difference in preventing drug-related harm.
For more information on ReadyGo Diagnostics Ltd., please visit www.readygotest.com. Additional information on SureScreen Diagnostics Ltd. can be found at www.surescreen.com.
Contacts:
ReadyGo Diagnostics Ltd.
Ben Cobb, Chief Executive Officer
Ben Reed, Chief Commercial Officer
info@readygotest.com
SureScreen Diagnostics Ltd.
David Campbell, Director
George Newham, Research and Development Manager
Craig McMillan, Head of Sales and Marketing
info@surescreen.com
Distributed by https://pressat.co.uk/
